Company profile

Company profileOfficial Gazette noticesNo confirmed enforcement recordJapanese original

丸善製薬株式会社

丸善製薬株式会社· Corporate Number: 8240001038553

This page aggregates company identity, Official Gazette notices, enforcement records, related-company signals, and source-review links into one public-record profile.

Current page: Company profile

This page brings together Official Gazette notices, enforcement records, registry data, related-company signals, and source-review links for one company. Open individual enforcement records from the history section below.

Free report

Save a public-record evidence report for 丸善製薬株式会社

Includes company identity, enforcement history, Official Gazette notices, source-review fields, and reviewer notes for internal due-diligence files.

Related tool Kiroku

Monitor website changes for 丸善製薬株式会社

Open Kiroku monitoring and enter the official website, terms, IR, pricing, or announcement URL you want to track.

Open website monitoring
For developers: JSON integration details

You do not need this for normal browsing. Use it when integrating this company record into an internal tool or AI workflow.

/api/v1/search?q=8240001038553&limit=5

Public Record Summary

Total enforcement
0records
Official Gazette
3notices
Actions in last 3 years
0records
Actions in last year
0records
Latest public record
7 Jul 2026
Total penalties
-
Registry changes
0items

Company Identity and Registry Data

English display name
丸善製薬株式会社
Original Japanese name
丸善製薬株式会社
Corporate Number
8240001038553
Registered address
広島県尾道市向東町14703番地の10

Note: Detailed gBizINFO registry data may not be available for this company yet. Use the public registry links below to review supplemental source information.

Corporate Number site: fetched 14 May 2026

Data sources

Official Gazette

Japanese Official Gazette company notices

3 notice(s)

Maruzen Pharmaceutical Co., Ltd. Financial Statements Notice for the 64th Term

Financial statements noticeFinancial report
Publication / issue / page
7 Jul 2026 Extra Edition 第152号 p.78
English summary
This is a financial statements notice published on July 7, 2026, reporting the balance sheet as of March 31, 2026, for Maruzen Pharmaceutical Co., Ltd.
Published company name
丸善製薬株式会社
Published address
広島県尾道市向東町14703番地の10
Translated excerpt
The summary of the balance sheet as of March 31, 2026 (Reiwa 8) for the 64th fiscal period.
Source
Official Gazette
Show original Japanese extracted fields
Original notice type
決算公告
Original related text
第64期決算公告 / 貸借対照表の要旨 (令和8年3月31日現在)
Original excerpt
第64期決算公告 / 貸借対照表の要旨 (令和8年3月31日現在)
Show official Japanese notice text

号外第 152 号 令和8年7月7日火曜日 官 報 (号  外) 公  告 会社その他の公告page="0078"page="0078"   第64期決算公告   令和8年7月7日広島県尾道市向東町14703番地の10  丸善製薬株式会社   代表取締役社長 日暮 泰広page="0078"貸借対照表の要旨    (令和8年3月31日現在)    (単位:百万円)科    目金 額 科    目金 額 流動資産17,592流動負債6,888固定資産14,532固定負債1,111うち退職給付引当金       (375)株主資本24,124資本金98資本剰余金27その他資本剰余金27利益剰余金23,999利益準備金24その他利益剰余金23,974(うち当期純利益)(1,519) 資産合計 32,124負債・純資産合計32,124©2010独立行政法人国立印刷局/National Printing Bureau. All rights reserved.

Official Gazette company notice

Official Gazette noticeCompany noticeTranslation pending
Publication / issue / page
7 Jul 2025 Extra Edition 第155号 p.100
English summary
Company notice
Published company name
丸善製薬株式会社
Published address
広島県尾道市向東町14703番地の10
Source
Official Gazette
Show original Japanese extracted fields
Original notice type
決算公告
Original related text
第63期決算公告 / 貸借対照表の要旨 (令和7年3月31日現在)
Original excerpt
第63期決算公告 / 貸借対照表の要旨 (令和7年3月31日現在)
Show official Japanese notice text

号外第 155 号 令和7年7月7日月曜日 官 報 (号  外) 公  告 会社その他の公告page="0100"page="0100"   第63期決算公告   令和7年7月7日広島県尾道市向東町14703番地の10  丸善製薬株式会社   代表取締役社長 日暮 泰広page="0100"貸借対照表の要旨    (令和7年3月31日現在)    (単位:百万円)科    目金 額 科    目金 額 流動資産17,883流動負債7,132固定資産13,605固定負債1,714うち退職給付引当金       (469)株主資本22,642資本金98資本剰余金27その他資本剰余金27利益剰余金22,517利益準備金24その他利益剰余金22,492(うち当期純利益)(1,033) 資産合計 31,488負債・純資産合計31,488©2010独立行政法人国立印刷局/National Printing Bureau. All rights reserved.

62nd Fiscal Year Financial Statements Notice

Financial statements noticeFinancial report
Publication / issue / page
5 Jul 2024 Extra Edition 第162号 p.100
English summary
This is a financial statements notice for the 62nd fiscal year, published on July 5, 2024, by Maruzen Pharmaceutical Co., Ltd. The balance sheet as of March 31, 2024, shows total assets of 30,225 million yen, with current assets of 17,710 million yen, fixed assets of 12,515 million yen, and liabilities totaling 8,590 million yen, including current liabilities of 6,958 million yen and fixed liabilities of 1,632 million yen. Shareholders' equity is 21,634 million yen.
Published company name
丸善製薬株式会社
Published address
広島県尾道市向東町14703番地の10
Translated excerpt
62nd fiscal year financial statements notice / Summary of balance sheet (as of March 31, 2024)
Source
Official Gazette
Show original Japanese extracted fields
Original notice type
決算公告
Original related text
第62期決算公告 / 貸借対照表の要旨 (令和6年3月31日現在)
Original excerpt
第62期決算公告 / 貸借対照表の要旨 (令和6年3月31日現在)
Show official Japanese notice text

号外第 162 号 令和6年7月5日金曜日 官 報 (号  外) 公  告 会社その他の公告page="0100"page="0100"   第62期決算公告   令和6年7月5日広島県尾道市向東町14703番地の10  丸善製薬株式会社   代表取締役社長 日暮 泰広page="0100"貸借対照表の要旨    (令和6年3月31日現在)    (単位:百万円)科    目金 額 科    目金 額 流動資産17,710流動負債6,958固定資産12,515固定負債1,632うち退職給付引当金       (543)株主資本21,634資本金98資本剰余金27その他資本剰余金27利益剰余金21,509利益準備金24その他利益剰余金21,484(うち当期純利益)(1,168) 資産合計 30,225負債・純資産合計30,225©2010独立行政法人国立印刷局/National Printing Bureau. All rights reserved.

Enforcement and administrative action history

No enforcement records are currently listed in RegBase's monitored sources.

RegBase automatically collects public disclosures from Japanese government sources. Non-public administrative guidance, oral warnings, and unpublished actions are not included. See data sources.

About this English name

No official English name source is recorded. The original Japanese name is shown.

If this profile contains an error or your company needs to add context, please use the correction request form. Submissions are reviewed under RegBase editorial policy.

This page mechanically aggregates and structures public government disclosures and public registry data under the editorial policy. It is not legal advice, credit scoring, or a final procurement decision. Always verify against the official source pages.